Life sciences biotech company Cybin Inc. (NYSE: CYBN) announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its proprietary deuterated DMT molecule, CYB004.

Anxiety disorders are the most common mental health concern in the US, with over 40 million adults (19.1% of total population) suffering from one. 

Specifically, GAD is a condition in which excessive worry and tension are present unrestricted to any specific environmental circumstances. It currently affects 6.8 million of US adults (3.1% of total …

Full story available on Benzinga.com